+++ Ihre Meinung ist uns wichtig: Wie zufrieden sind Sie mit finanzen.ch? - Hier an unserer Umfrage teilnehmen! +++ -w-
<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Strukturierte Produkte
>
13.10.2019 18:00:00

2 Biotechs With Approaching Drug Approvals To Own Today

Drug development is hard and expensive, but so is commercialization. Biotechs that persevere and make it through late-stage pivotal trials face the challenges of gaining regulatory approval. Many biotech companies will never endure this because promising drug candidates often get licensed by more established commercial players with experience bringing new drugs to market.Preparing to launch a new drug can be quite expensive, particularly for large, fragmented patient populations. We will explore one company that recently had its first regulatory submission accepted for review and another that plans to refile its application by the end of the year.Photo by Thought CatalogContinue reading
Weiter zum vollständigen Artikel bei "MotleyFool"

Analysen zu With Incmehr Analysen

Eintrag hinzufügen

Amun startet mit ETPs in CHF an der BX Swiss | BX Swiss TV

Finanzen.net News

pagehit